Skip to main content

Table 1 Eligibility criteria

From: The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial

Inclusion criteria Exclusion criteria
Subjects > 18 years of age Contraindication for use of ARB
Either gender Urgent need for revascularization procedure
First episode of acute MI Severe heart failure (NYHA IV or need for inotropic support)
Typical pain lasting ≥ 20 minutes Persistent (>1 hour) severe hypotension (systolic blood pressure < 90 mmHg)
ST elevation of more than 1 mm in at least 2 separate leads on the ECG Refractory or potentially lethal arrhythmias
An echocardiographic LV EF < 50% Hemodynamically significant right ventricular infarction
Optimal recording of echocardiographic imaging of apical chamber views Congenital heart disease
Patients who provide written informed consent Primary valvular disease, severer than mild degree
  Idiopathic hypertrophic cardiomyopathy
  Concomitant inflammatory cardiomyopathy
  Significant renal dysfunction (serum creatinine 2.5 mg/dl)
  Significant hepatic dysfunction (serum transaminase more than 3 times normal)
  Anemia (hemoglobin < 10 mg/mL or 6 mmol/L)
  Psychiatric disorders, alcohol or drug abuse
  Life expectancy is less than 1 year
  Participation in any other pharmacological study within 2 months
  Refusal or inability to provide informal consent